Hypertension, aspirin, renin-angiotensin-aldosterone system Hypertensie, aspirine, renine-angiotensine-aldosteronsysteem
Conditions
Interventions
After patient’s written informed consent and screening, subjects will be randomised between 100 mg aspirin at awakening and at bedtime in two treatment periods of 2 weeks. They will also get a placebo
Sponsors
Leiden University Medical Center
Vascular Medicine Unit
Department of General Internal Medicine and Endocrinology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Essential hypertension, without treatment <160/100 mm Hg, with treatment <140/90 mm Hg. If treated, treatment should be stopped before entering into study. 2. Age 18-80 year 3. Capacity to give informed consent
Exclusion criteria
Exclusion criteria: 1. Moderate or severe hypertension (>160/100) 2. Secondary hypertension 3. Personal history of cardiovascular events 4. Diabetes mellitus 5. Rheumatoid arthritis 6. Vasoactive medication 7. Any contraindication to use of aspirin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Renin-angiontensin-aldosterone system represented by renin activity | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are other determinants of RAAS-activity, markers of autonomous nervous system activity, COX-inhibition, vascular wall inflammation, vascular adhesion molecules and coagulation. We also measure 24-h blood pressure as well as central arterial stiffness (by non-invasive pulse wave analysis) to determine whether blood pressure effects are more centrally or peripherally located. | — |
Contacts
Public ContactM.V. Huisman
Leiden University Medical Center (LUMC) Department of Thrombosis and Haemostasis Room C4-68 P.O Box 9600
Outcome results
None listed